Klacid Paediatric Suspension (Clarithromycin)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation step of peptide chain elongation. This action stops bacterial growth, providing a bacteriostatic effect against a range of Gram‑positive and some Gram‑negative pathogens.

The dosage of Klacid Paediatric Suspension is determined by the prescribing clinician based on the child’s age, weight, infection type, and severity. The prescriber will calculate the appropriate amount and frequency according to approved pediatric dosing guidelines.

The pregnancy category for clarithromycin is listed as unknown, and safety data for use in pregnant or nursing mothers are limited. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or breastfeeding patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Clarithromycin belongs to the macrolide class, offering a broad spectrum against atypical and some resistant bacteria. Compared with beta‑lactams, it provides coverage for organisms like Mycoplasma and Legionella and is often chosen when patients have penicillin allergies or when macrolide activity is specifically required.

The suspension should be stored at ambient temperature, below 25 °C, in its original container. Keep it away from moisture, direct sunlight, and heat sources. Shake well before each use to ensure uniform drug distribution.

Klacid Paediatric Suspension is taken orally. The prescribed dose is measured with a calibrated syringe or dosing cup to ensure accuracy. It can be given with or without food, but taking it with a small amount of food may reduce gastrointestinal upset.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatotoxicity, QT interval prolongation leading to cardiac arrhythmias, and rare skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for any signs of these conditions.

Children with a known hypersensitivity to clarithromycin, other macrolides, or any component of the formulation should avoid this product. It is also contraindicated in patients with a history of significant QT prolongation or those taking medications that strongly interact with clarithromycin without appropriate monitoring.